Journal
SWISS MEDICAL WEEKLY
Volume 142, Issue -, Pages -Publisher
E M H SWISS MEDICAL PUBLISHERS LTD
DOI: 10.4414/smw.2012.13511
Keywords
DLBCL; first-line treatment; maintenance treatment; relapsed/refractory disease; rituximab; chemotherapy; staging; follow-up
Categories
Funding
- Roche Pharma (Schweiz) AG, Reinach, Switzerland
Ask authors/readers for more resources
Diffuse large B-cell lymphoma (DLBCL) is the most frequently-occurring type of malignant lymphoma in the Western world. It has an aggressive natural history, with a median survival of less than one year if left untreated. Immunochemotherapy regimens, consisting of the anti-CD20 antibody rituximab typically in combination with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP), are currently the treatment backbone. Despite remarkable progress in improving patient survival, clinical outcomes are still unsatisfactory for certain subsets of patients, including the elderly and very elderly and those with highly aggressive disease. This review outlines some of the current treatment strategies for DLBCL and discusses the main issues that affect clinical practice.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
